Search

Displaying results 8741 - 8750 of 10000 in total
  1. Drug

    Afuresertib

    go.drugbank.com/drugs/DB11648
    Investigational

    Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.

  2. Drug

    2-phospho-D-glyceric acid

    go.drugbank.com/drugs/DB01709
    Experimental

    A 2-phosphoglyceric acid in which the glyceric acid moiety has D (R) configuration.

  3. Drug

    Acotiamide

    go.drugbank.com/drugs/DB12482
    Investigational

    Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.

  4. Drug

    Varegacestat

    go.drugbank.com/drugs/DB13126
    Investigational

    BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.

  5. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  6. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.

  7. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  8. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administrat...

  9. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected...

  10. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma.